EUVIMEDEUVIMED entdecken
Crossref

Development of APH003─a Highly Potent, Selective, and Orally Bioavailable IRAK4 PROTAC Degrader for the Treatment of Inflammatory Diseases

Xi-Wei Wu iD, Zhao-Min Chen, Cui Gao, Mi Tian, Xi-Le Liu, Hui Wang, Hai-Jie Chen, Han-Xiong Li, Wen-Qian Yang, Lin-Kun An iD

Journal of Medicinal Chemistry · 09.07.2026 · 69 (13) · 15685-15701

DOI: 10.1021/acs.jmedchem.6c00828 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 26.06.2026. Verfasst von Xi-Wei Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China. Hauptthemen laut MEDLINE: Interleukin-1 Receptor-Associated Kinases, Inflammation, Anti-Inflammatory Agents. Die Arbeit nennt 37 Literaturangaben. Gefördert von: ApicHope Pharmaceutical Group Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-1 Receptor-Associated KinasesInflammationAnti-Inflammatory AgentsAnimalsHumansProteolysis Targeting ChimeraDogsRatsAdministration, OralBiological AvailabilityStructure-Activity RelationshipMaleRats, Sprague-Dawley

Substanzen

Interleukin-1 Receptor-Associated KinasesProteolysis Targeting ChimeraIRAK4 protein, humanAnti-Inflammatory Agents

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
  • ApicHope Pharmaceutical Group Co, Ltd., Guangzhou 510000, China.
  • State Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China.
  • Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, Guangzhou 510006, China.

ORCID-Profile: Xi-Wei Wu, Lin-Kun An

Förderung

  • ApicHope Pharmaceutical Group Co., Ltd.

Zitieren

APA

Wu, X. W., Chen, Z. M., Gao, C., Tian, M., Liu, X. L., Wang, H., Chen, H. J., Li, H. X., Yang, W. Q., & An, L. K. (2026). Development of APH003─a Highly Potent, Selective, and Orally Bioavailable IRAK4 PROTAC Degrader for the Treatment of Inflammatory Diseases. Journal of Medicinal Chemistry, 69(13), 15685-15701. https://doi.org/10.1021/acs.jmedchem.6c00828

Vancouver

Wu XW, Chen ZM, Gao C, Tian M, Liu XL, Wang H, et al. Development of APH003─a Highly Potent, Selective, and Orally Bioavailable IRAK4 PROTAC Degrader for the Treatment of Inflammatory Diseases. Journal of Medicinal Chemistry. 2026;69(13):15685-15701. doi:10.1021/acs.jmedchem.6c00828

BibTeX
@article{Wu2026,
  author = {Wu, Xi-Wei and Chen, Zhao-Min and Gao, Cui and Tian, Mi and Liu, Xi-Le and Wang, Hui and Chen, Hai-Jie and Li, Han-Xiong and Yang, Wen-Qian and An, Lin-Kun},
  title = {Development of APH003─a Highly Potent, Selective, and Orally Bioavailable IRAK4 PROTAC Degrader for the Treatment of Inflammatory Diseases},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {13},
  pages = {15685--15701},
  doi = {10.1021/acs.jmedchem.6c00828}
}
Kostenlos starten →